Maintain & Adapt Pharma Market Access Digital Tools Using Feedback Blog Post
Maintain the credibility of your pharma market access digital tools through continuous updates based on user feedback. Learn more…
The Do’s and Don’ts of Define.xml Blog Post
Discover the 6 dos and don’ts of creating compliant define.xml files for FDA submission with our free, downloadable Define-XML format guide.
Latest Phoenix PK/PD analysis & modeling platform release prioritizes efficiency, power Blog Post
2025年6月16日 RADNOR, PA – 2025年6月16日 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in model-informed drug development, today announced the launch of Phoenix™ version 8.6. Phoenix...
Modernizing NCA Workflows: The Power of ADNCA for Regulatory-Ready Pharmacokinetic Analysis Blog Post
[event_date_range]
EACPT 2025 CONGRESS Blog Post
[event_date_range] – [acf field="event_location"] – Booth [acf field="event_booth"]
What are the most common in vitro drug-drug interaction study gaps? Blog Post
Certara drug interaction science experts share data and experimental design gaps commonly found in in vitro drug-drug interaction studies.
Systems modeling helps optimize safety and efficacy for oncolytic viruses Blog Post
2025年5月30日 Gene therapies delivered in viral vectors offer an exciting and challenging approach to targeted cancer therapy. Systems modeling for oncolytic viruses can help drug developers characterize safe...
CERTAINTY 2025: The power of Model-Informed Drug Development Blog Post
We cover the key takeaways from CERTAINTY 2025, including the power of Model-Informed Drug Development and the role of AI in reducing time to submission.
